STERIS earnings date and guidance
MyStockButler's October 2026 analysis: STERIS's next results are expected on November 4, 2026. Watch STERIS's cash generation and project milestones.
What has STERIS guided for FY2027?
STERIS helps hospitals and manufacturers prevent infection with equipment, chemicals and sterilization services. For FY2027, management guides to reported revenue growth of 7.0%–8.0%. It guides to constant-currency organic growth of 6.0%–7.0%.
Management expects adjusted EPS of $11.10–$11.30. Reported continuing-operations EPS is guided to $8.92–$9.12 because adjusted EPS excludes selected accounting costs, including $2.08 a share of acquired-intangible amortization. That charge is usually non-cash today, but the acquisition that created the asset required real cash.
The cash promise is $1,250.0 million from operations and $800.0 million of free cash flow after $450.0 million of capital spending. The capital-spending figure already includes approximately $75 million for North Carolina, so that construction cost must not be deducted twice.
| Period guided | Low | High | Date given | |
|---|---|---|---|---|
| as reported revenue growth | Year to Mar 2027 | 7.0% | 8.0% | Aug 5, 2026 |
| constant currency organic revenue growth | Year to Mar 2027 | 6.0% | 7.0% | Aug 5, 2026 |
| Net income from continuing operations per diluted share | Year to Mar 2027 | 8.92 | 9.12 | Aug 5, 2026 |
| Adjusted net income from continuing operations per diluted share | Year to Mar 2027 | 11.10 | 11.30 | Aug 5, 2026 |
| Cash flows from operating activities | Year to Mar 2027 | 1,250.0 | 1,250.0 | Aug 5, 2026 |
| Free Cash Flow | Year to Mar 2027 | 800.0 | 800.0 | Aug 5, 2026 |
What this means. These are the company's forecasts, not results already achieved, and they exclude the pending Xodus acquisition.
Did STERIS keep its past promises?
The record is mixed. Adjusted EPS met or exceeded initial guidance four times out of five, while revenue and cash each did so three times. That makes the earnings promise reasonably credible, but it does not make cash conversion equally dependable.
| What management forecast | Checked | Above | Within | Below |
|---|---|---|---|---|
| As reported revenue | 5 years | 3 | 0 | 2 |
| Adjusted earnings per diluted share | 5 years | 3 | 1 | 1 |
| Free cash flow | 5 years | 3 | 0 | 2 |
What this means. The free cash flow numbers include the Dental business, so they may not show only the company’s continuing business.
How has STERIS's revenue and profit trended?
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,492.7 | 1,588.4 | 1,496.2 | 1,460.3 | 1,391.1 | 1,480.5 | 1,370.6 | 1,328.9 |
| Operating income | 285.8 | 316.8 | 273.2 | 265.8 | 246.0 | 216.1 | 245.3 | 219.7 |
| Net income | 200.1 | 220.3 | 192.9 | 191.9 | 177.4 | 146.5 | 173.6 | 150.2 |
| EPS, diluted | 2.04 | 2.24 | 1.96 | 1.94 | 1.79 | 1.48 | 1.75 | 1.51 |
What this means. Each column covers one quarter, so the descriptions that say “year” are misleading.
What should STERIS watch on November 4, 2026?
STERIS plans to report its September-quarter results on November 4, 2026, followed by its call on November 5. Investors should examine customer collections, inventory, capital spending and buybacks together. Higher earnings accompanied by unpaid invoices or unsold stock would leave less cash for construction.